Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Deffered Revenue: 2010-2016

Historic Non-Current Deffered Revenue for Anika Therapeutics (ANIK) over the last 7 years, with Dec 2016 value amounting to $48,000.

  • Anika Therapeutics' Non-Current Deffered Revenue fell 27.27% to $48,000 in Q4 2016 from the same period last year, while for Dec 2016 it was $48,000, marking a year-over-year decrease of 27.27%. This contributed to the annual value of $48,000 for FY2016, which is 27.27% down from last year.
  • Latest data reveals that Anika Therapeutics reported Non-Current Deffered Revenue of $48,000 as of FY2016, which was down 27.27% from $66,000 recorded in FY2015.
  • In the past 5 years, Anika Therapeutics' Non-Current Deffered Revenue registered a high of $2.2 million during FY2012, and its lowest value of $48,000 during FY2016.
  • Its 3-year average for Non-Current Deffered Revenue is $72,000, with a median of $66,000 in 2015.
  • Data for Anika Therapeutics' Non-Current Deffered Revenue shows a maximum YoY plummeted of 95.04% (in 2014) over the last 5 years.
  • Yearly analysis of 5 years shows Anika Therapeutics' Non-Current Deffered Revenue stood at $2.2 million in 2012, then declined by 4.54% to $2.1 million in 2013, then plummeted by 95.04% to $102,000 in 2014, then slumped by 35.29% to $66,000 in 2015, then fell by 27.27% to $48,000 in 2016.